| Yao P, Zhai X, Liu D, et al.
Synthesis and Antiproliferative Activitiy of Novel Diaryl Ureas Possessing a 4H-Pyrido[1,2-a]pyrimidin-4-one Group. [JOURNAL ARTICLE]
Arch Pharm (Weinheim) 2009 Nov 19.
Abstract | Full Citation |
| Cabrera R, Nelson DR
Review article: management of hepatocellular carcinoma. [JOURNAL ARTICLE]
Aliment Pharmacol Ther 2009 Nov 19.
Abstract | Full Citation |
| Tai CJ
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma. [JOURNAL ARTICLE]
Acta Oncol 2009; 48(6):931-932.
Full Citation |
| Lipworth AD, Robert C, Zhu AX
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib. [JOURNAL ARTICLE]
Oncology 2009 Nov 16; 77(5):257-271.
Abstract | Full Citation | Find Related Articles |
| Moretti LV, Montalvo RO
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. [JOURNAL ARTICLE]
Am J Health Syst Pharm 2009 Dec 1; 66(23):2123-2125.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Carter CA, Rajan A, Giaccone G
Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report. [Journal Article]
Cases J 2009.:6264.
Abstract | Full Citation | Find Related Articles |
| Karreth FA, DeNicola GM, Winter SP, et al.
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). [Journal Article, Research Support, Non-U.S. Gov't]
Mol Cell 2009 Nov 13; 36(3):477-86.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Hasinoff BB, Patel D
Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib. [JOURNAL ARTICLE]
Cardiovasc Toxicol 2009 Nov 14.
Abstract | Full Citation |
| Miyake H, Kurahashi T, Yamanaka K, et al.
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation. [JOURNAL ARTICLE]
Urol Oncol 2009 Nov 12.
Abstract | Full Citation | Find Related Articles |
| Chen KF, Yu HC, Liu TH, et al.
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. [JOURNAL ARTICLE]
J Hepatol 2009 Oct 23.
Abstract | Full Citation | Find Related Articles |
  |
